Key Highlights
- Fiscal second quarter adjusted EPS was USD 2.94 against a USD 2.68 estimate, while reported diluted EPS was USD 2.19.
- Revenue was USD 1,588.6 million against USD 1,460.3 million a year ago, with constant currency organic growth of 8%.
- Life Sciences Revenue was USD 170.6 million, with Capital equipment revenue up 53% and Operating Income of USD 75.8 million.
- Fiscal 2027 adjusted EPS guidance is USD 11.35 to USD 11.55, against a prior USD 11.10 to USD 11.30.
STERIS (NYSE:STE) reported fiscal 2027 second quarter adjusted EPS of USD 2.94, against an estimate of USD 2.68 and USD 2.47 in the prior-year quarter. As reported diluted EPS was USD 2.19, against USD 1.94. Revenue for the quarter ended September 30, 2026 was USD 1,588.6 million against USD 1,460.3 million, and the company raised its full year adjusted EPS guidance while describing a Tariff refund benefit and a new restructuring plan.
Results for the Second Quarter
Net income attributable to shareholders was USD 213.7 million against USD 191.9 million. Adjusted Net Income was USD 286.8 million against USD 244.5 million. Income from operations was USD 294.3 million against USD 265.8 million.
Management said the pre-tax effect of tariff refunds on reported results was a benefit of about USD 20 million, while gross tariff costs were flat with the prior year at USD 15 million. Restructuring expenses were USD 19.1 million against USD 2.2 million. Chief executive Dan Carestio described fiscal 2027 as shaping up to be a record year and said Life Sciences prompted a higher segment view.
Healthcare, AST and Life Sciences Segments
Healthcare revenue was USD 1,122.4 million against USD 1,033.8 million, with service revenue up 10%, consumables up 10% and capital equipment up 4%. Segment operating income was USD 269.2 million against USD 259.5 million.
Applied Sterilization Technologies revenue was USD 295.6 million against USD 281.5 million, with service revenue up 5% and capital equipment revenue down 21%. Operating income was USD 132.1 million against USD 127.6 million.
Life Sciences revenue was USD 170.6 million against USD 145.0 million. Capital equipment revenue rose 53%, consumables 9% and service 5%. Operating income was USD 75.8 million against USD 59.9 million.
Cash Flow, Capital Returns and Restructuring
Cash from operations for the first six months was USD 656.1 million against USD 707.8 million, and free Cash Flow was USD 492.5 million against USD 527.7 million. The company attributed the lower figures mainly to a smaller Working Capital contribution. Cash and cash equivalents were USD 531.1 million at September 30, with long-term indebtedness of USD 1,650.3 million.
Six-month repurchases of ordinary shares totaled USD 215.9 million against USD 111.1 million, and dividends paid were USD 128.4 million. The quarterly Dividend declared was USD 0.69 per share against USD 0.63.
During the quarter the company approved a separate restructuring plan covering Facility realignment, product rationalization and organizational realignment, mainly in Healthcare. It cited total charges of about USD 45 million, including about USD 10 million in cash, with about USD 25 million recorded in the quarter and annualized savings of about USD 9 million.
Fiscal 2027 Guidance
Adjusted EPS guidance moved to USD 11.35 to USD 11.55 from USD 11.10 to USD 11.30, and the company said the revision includes about USD 0.18 from tariff refunds received so far. As reported revenue growth is guided at 7% to 8% and constant currency organic growth at 6% to 7%, both unchanged. Free cash flow is guided at USD 800 million.
Constant currency organic growth guidance for Life Sciences is 9% to 10%, up from 6% to 7%, while Applied Sterilization Technologies moved to 6% to 7% from 7% to 8%. Healthcare remains at 6% to 7%.
Numbers in Context
Adjusted EPS of USD 2.94 sits alongside as reported diluted EPS of USD 2.19, revenue of USD 1,588.6 million and six-month free cash flow of USD 492.5 million.
Management stated that a revised fiscal 2027 outlook including the proposed Xodus Medical Acquisition would follow after closing. A conference call was scheduled for November 5, 2026.






Please wait processing your request...